Wiley
Wiley.com
Print this page Share

From Genome to Therapy: Integrating New Technologies with Drug Development, Number 229

ISBN: 978-0-471-62744-9
Hardcover
174 pages
November 2000
US $205.00 Add to Cart

This price is valid for United States. Change location to view local pricing and availability.

From Genome to Therapy: Integrating New Technologies with Drug Development, Number 229 (0471627445) cover image
This is a Print-on-Demand title. It will be printed specifically to fill your order. Please allow an additional 5-6 days delivery time. The book is not returnable.

This important and exciting work brings together a high-calibre group of experts to discuss the practical application of genomic information to the development of drugs. Recent technological advances have led to a rapid acceleration in our ability to gather genetic data. The complete genetic sequences are now known for several organisms and accelerated programmes are in place for sequencing many other genomes, including human. The speed with which complete sequencing can be accomplished will continue to increase as new technologies come online. In principle, the scope for developing new diagnostic techniques and drugs is now greater than at any time in human history, but the pathway from genetic information to usable drug is a long and complex one.

This major book covers such subjects as the current state of the art in squencing technology, the applications of these new technologies to sequencing the genomes of various organisms, and the challenge of proteomics. Additional contributions deal with legal and ethical implications of the new uses of genetic data, and functional genomics from the point of view of the pharmaceutical industry.

Buy Both and Save 25%!

+

From Genome to Therapy: Integrating New Technologies with Drug Development, Number 229 (US $205.00)

-and- Pharmacogenomics (US $159.95)

Total List Price: US $364.95
Discounted Price: US $273.71 (Save: US $91.24)

Add BOTH to Cart
Cannot be combined with any other offers. Learn more.